Lexicon Pharmaceuticals (LXRX +4%) is up on below-average volume on the heels of positive results from a Phase 1 multiple ascending-dose clinical trial evaluating neuropathic pain candidate LX9211 in healthy volunteers.
LX9211 demonstrated a favorable safety profile and pharmacokinetic activity supportive of once-daily dosing. The most common adverse events were headache and dizziness.
Small molecule LX9211 inhibits an enzyme called adaptor-associated protein kinase 1 (AAK1). The company acquired exclusive rights from development partner Bristol-Myers Squibb two years ago.
Development is ongoing.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.